依立替康联合卡培他滨治疗晚期胃癌的临床观察

目的：观察依立替康（CPT-11）联合卡培他滨（CAP）治疗晚期胃癌的近期疗效和毒副反应。方法：CPT-11100mg/m2d1,8CAP1000mg/m2Po一日两次,连用14天,21天为一周期,2个周期后评价疗效及毒副反应。结果：26例患者,有效率为30.8%,中位无进展生存期为6.4个月,中位OS为12.2个月,主要毒副反应为胃肠道反应和骨髓抑制,无化疗相关死亡。结论：CPT-11联合CAP方案治疗晚期胃癌有较好疗效。

Clinical Observation Irinotecan in Combination with Capecitabine in the Treatment of Advanced Gastric Cancer

Objective: The aim of this study is to observe the efficacy and toxic side effects of irinotecan(CPT-11) in combination with capecitabine(CAP) in patients with advanced gastric cancer.Method: Drugs are taken as this: CPT-11 100 mg/m2,d1,8,CAP1000 mg/m2,Po,twice a day,once every 14 days.The efficacy and toxicity are evaluated after two cycles.Results: of 26 patients,effective rate was 30.8%,with a median progression-free survival 6.4 months,and median OS 12.2 months.The main toxicities were gastrointestinal reactions and bone marrow suppression,no chemotherapy-related deaths.Conclusion: CPT-11 combined with CAP regimen in advanced gastric cancer has a good effect.